New Drug Approvals

Home » Uncategorized » AUR 101

AUR 101



Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 


Recent Posts

Blog Stats

  • 4,041,205 hits

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,752 other followers

add to any


AUR 101



AUR-101, a ROR gamma inverse agonist for autoimmune disorders like psoriasis

AUR-101 is an ROR-gammaT inverse agonist in phase II clinical development at Aurigene for the treatment of patients with moderate-to-severe chronic plaque-type psoriasis.

  • DrugsAUR 101 (Primary)
  • IndicationsPlaque psoriasis
  • FocusAdverse reactions; First in man
  • AcronymsINDUS
  • SponsorsAurigene Discovery Technologies
  • OriginatorAurigene Discovery Technologies
  • ClassAntipsoriatics; Small molecules
  • Mechanism of ActionNuclear receptor subfamily 1 group F member 3 inverse agonists
  • Phase IIPsoriasis

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate


This image has an empty alt attribute; its file name is research.jpg

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@amcrasto




Aurigene Announces First Patient Dosed with AUR101 in Phase II Study in Patients with Moderate to Severe Psoriasis

Bangalore, February 17, 2020 — Aurigene, a development stage biotechnology company, today announced dose administration for the first patient in INDUS-2, a Phase II double blind placebo-controlled three-arm study of AUR101 in patients with moderate to severe psoriasis. AUR101 is an oral small molecule inverse agonist of RORγ and has shown desirable pharmacodynamic modulation of IL-17 and acceptable safety in a completed Phase I human study conducted in Australia.

“The initiation of this Phase II study under a US FDA IND represents a significant milestone for Aurigene, as it marks the first program which Aurigene has led from the bench side to the clinic all by itself,” said Murali Ramachandra, PhD, Chief Executive Officer of Aurigene. “We look forward to producing important clinical data by the end of 2020 to guide our future development plans and demonstrating Aurigene’s unique expertise in conducting Proof-of-Concept studies in a quality and fast-paced manner.”

About AUR101-201 and the Phase II Study of AUR101 in Patients with Moderate to Severe Psoriasis

The purpose of the Phase II multi-center, blinded, placebo-controlled, three-arm study is to evaluate the clinical activity of AUR101 in patients with moderate to severe psoriasis. In two of the arms, AUR101 will be administered twice daily, at 400 mg PO BID and 600 mg PO BID, for 12 weeks. Patients in the third arm will receive matched blinded placebo in a double dummy fashion. The trial is listed at with identifier NCT04207801.

About Aurigene

Aurigene is a development stage biotech company engaged in discovery and clinical development of novel and best-in-class therapies to treat cancer and inflammatory diseases and a wholly owned subsidiary of Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY,NYSE: RDY). Aurigene is focused on precision- oncology, oral immune checkpoint inhibitors, and the Th-17 pathway. Aurigene currently has several programs from its pipeline in clinical development. Aurigene has also submitted an IND to DCGI, India for a Phase IIb/III trial of CA-170, a dual inhibitor of PD-L1 and VISTA, in non-squamous NSCLC. Additionally, Aurigene has multiple compounds at different stages of pre-clinical development. Aurigene has partnered with many large and mid-pharma companies in the United States and Europe and has 15 programs currently in clinical development. For more information, please visit Aurigene’s website at


Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways

M.A.X. Tollenaere,J. Hebsgaard,D.A. Ewald,P. Lovato,S. Garcet,X. Li,S.D. Pilger,M.L. Tiirikainen,M. Bertelsen,J.G. Krueger,H. Norsgaard,First published: 01 April 2021 2Funding sources LEO Pharma A/S funded this study.Conflicts of interest M.A.X.T., J.H., D.A.E., P.L., S.D.P., M.L.T., M.B. and H.N. are employees of LEO Pharma. J.G.K. received grants paid to his institution from Novartis, Pfizer, Amgen, Lilly, Boehringer, Innovaderm, BMS, Janssen, AbbVie, Paraxel, LEO Pharma, Vitae, Akros, Regeneron, Allergan, Novan, Biogen MA, Sienna, UCB, Celgene, Botanix, Incyte, Avillion and Exicure; and personal fees from Novartis, Pfizer, Amgen, Lilly, Boehringer, Biogen Idec, AbbVie, LEO Pharma, Escalier, Valeant, Aurigene, Allergan, Asana, UCB, Sienna, Celgene, Nimbus, Menlo, Aristea, Sanofi, Sun Pharma, Almirall, Arena and BMS.Data Availability Statement The gene array dataset described in this publication has been deposited in NCBI’s Gene Expression Omnibus and is accessible through GEO Series accession number GSE158448 (


10:35 Small Molecule Inhibitors of RORgamma and IRAK4 for the Treatment of Autoimmune Disorders

Susanta_SamajdarSusanta Samajdar, Ph.D., Director, Medicinal Chemistry, Aurigene Discovery Technologies Limited

Although biologics such as anti-TNFα antibody are fairly successful in the treatment of autoimmune disorders, there is significant unmet need due to heterogeneity in diseases and lack of response to established therapies in some patients. While biologics typically target one cytokine signaling pathway, small molecule therapeutics directed towards intracellular target(s) can interfere in the signaling from multiple cytokines potentially leading to improved response. Development of small molecule oral inhibitors of IRAK4 and RORgamma to target TLR/IL-R and Th17 pathway respectively will be discussed.


2448/CHE/2015 15.05.2015 IN



This application claims the benefit of Indian provisional application number 5641/CHE/2013 filed on 06th December 2013 which hereby incorporated by reference.


  • PANDIT, Chetan


2-​Quinolinecarboxamide​, 6-​(2,​6-​dimethyl-​4-​pyrimidinyl)​-​N-​[[4-​(ethylsulfonyl)​phenyl]​methyl]​-​5,​6,​7,​8-​tetrahydro-​6-​methyl-​5-​oxo-​, (6S)​-

Molecular Weight492.59, C26 H28 N4 O4 S




2013239366 CA 170





///////////////////////AUR 101, AURIGENE, ROR, IL-17, PHASE 2, CDSCO, Ravi Ujjinamatada, KOTRABASAIAH UJJINAMATADA Ravi, PANDIT Chetan, AUR101-201, plaque-type psoriasis

Ravi Ujjinamatada

Ravi Ujjinamatada

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.


Follow New Drug Approvals on

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,752 other followers


DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK LIFE SCIENCES LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 30 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, Dr T.V. Radhakrishnan and Dr B. K. Kulkarni, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 30 PLUS year tenure till date June 2021, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 90 Lakh plus views on dozen plus blogs, 233 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 33 lakh plus views on New Drug Approvals Blog in 233 countries...... , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc

Personal Links

View Full Profile →


  • RT @aasiri: الكيرالية Chirality الذرة الكيرالية هي الذرة التي تحتوي على اربع مجموعات مختلفة. هناك قواعد لتحديد كون المركب التشكل R او S.… 5 hours ago
  • RT @csiriiim: @csiriiim celebrates the 81st #foundation day of @CSIR_IND. Prof. Amitabha Chattopadhyay, CSIR Bhatnagar Fellow was the chief… 5 hours ago
  • RT @csiriict: सीएसआईआर-भारतीय रासायनिक प्रौद्योगिकी संस्थान (सीएसआईआर-आईआईसीटी), हैदराबाद में दिनांक 03 अक्टूबर, 2022 को हिंदी पखवाड़ा समाप… 5 hours ago
  • Glenmark Pharmaceuticals Ltd up for five straight sessions 5 hours ago
  • RT @csir_ncl: 30 सितंबर 2022 को हिन्दी पखवाड़ा समारोह पुरस्कार वितरण एवं एनसीएल आलोक पत्रिका विमोचन कार्यक्रम का आयोजन किया गया, जिसमें मु… 14 hours ago
  • @realsimranahuja… 14 hours ago
  • @realsimranahuja… 14 hours ago
  • RT @aasiri: هل يمكن ان تتحمل توربينات توليد الطاقة من الرياح الظروف الصعبة في القطب الشمالي من برودة تصل الى -17 درجة مئوية. نعم بالامكان ت… 1 day ago
  • RT @aasiri: السليلوز يتكون #السيليلوز من سلسلة من وحدات سكر #الجلوكوز متحدة مع بعضها مكونة #مبلمر. ويعتبر السيليلوز من اكثر #البوليمرات ا… 1 day ago
  • RT @csiriiim: Two days #Startup #Expo was organised by @CSIR_IND as part of Äzadi Ka #AmritMahotsav. The mega expo was inaugurated by hon’b… 1 day ago
  • RT @CSIR_IND: On the occasion of Gandhi Jayanti, Officers and employees of CSIR did shramdaan and plantation at CSIR Head Quarter at Anusan… 1 day ago
  • RT @aasiri: #التكنولوجيا في المستقبل، يمكن إجراء العمليات الجراحية عن بعد من بلد آخر من العالم #الذكاء_الاصطناعي #الانترنت https://t.c… 1 day ago
  • RT @visitmaldives: Heavenly Spa at The Westin Maldives Miriandhoo Resort recognized as ‘The Best Hotel Spa in the Indian Ocean’ by Haute Gr… 1 day ago
  • RT @IndiaDST: #SpecialCampaign2 .0 for Swachhta & Disposal of Pending Matters launched in @IndiaDST on 02.10.2022 on the birth anniversary… 1 day ago
  • RT @CSIR_IND: On the occasion of Gandhi Jayanti, Officers and employees of CSIR did shramdaan and plantation at CSIR Head Quarter at Anusan… 1 day ago


Follow my blog with Bloglovin The title of your home page You could put your verification ID in a comment Or, in its own meta tag Or, as one of your keywords Your content is here. The verification ID will NOT be detected if you put it here.
%d bloggers like this: